SCHEMBL4511328

SCHEMBL4511328

CCN1CCN(CCCC(=O)c2ccccc2C)CC1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.67
DRD4 P21917 4/20 0.67
CHRM1 P11229 3/20 0.67
CHRM2 P08172 1/20 0.67
CHRM4 P08173 1/20 0.67
HTR1A P08908 1/20 0.67
CHRM5 P08912 1/20 0.67
ADRA2A P08913 1/20 0.67
ADRA2B P18089 1/20 0.67
CHRM3 P20309 1/20 0.67
ADRA1D P25100 1/20 0.67
ADRA1A P35348 1/20 0.67
HRH1 P35367 1/20 0.67
ADRA1B P35368 1/20 0.67
DRD3 P35462 3/20 0.48
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 1/20 0.48
PKM P14618 1/20 0.48
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4501010 0.91 DRD2 (0.75) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL4498490 0.91 DRD2 (0.71) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL4504985 0.90 DRD2 (0.65) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL4498435 0.89 CHRM1 (0.72) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL4498591 0.89 DRD2 (0.64) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL4500534 0.88 DRD2 (0.67) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL4486407 0.87 CHRM1 (0.65) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL4494415 0.85 HTR1A (0.60) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL4557706 0.85 CHRM1 (0.60) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL7752357 0.84 DRD2 (0.62) DRD2DRD4CHRM1CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7485651-B2 Compounds with activity on muscarinic receptors ACADIA PHARMACEUTICALS, INC. (US) 2009-02-03 US disclosed
US-20080108618-A1 COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS BRANN MARK 2008-05-08 US disclosed
US-20030144285-A1 Compounds with activity on muscarinic receptors BRANN MARK (US) 2003-07-31 US disclosed
US-6528529-B1 4-Methoxy-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine ACADIA PHARMACEUTICALS INC. 2003-03-04 US disclosed
WO-2001005763-A2 COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS ACADIA PHARMACEUTICALS, INC. (US) 2001-01-25 WO disclosed
EP-1068185-A1 COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS Acadia Pharmaceuticals Inc. (US) 2001-01-17 EP disclosed
WO-1999050247-A1 COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS ACADIA PHARMACEUTICALS, INC. (US) 1999-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108618-A1 COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS CHRM3, CHRM2, CHRM1 DRD2 470/4885DRD4 824/4885CHRM1 3/4885
US-20030144285-A1 Compounds with activity on muscarinic receptors CHRM3, CHRM2, CHRM1 DRD2 470/4885DRD4 824/4885CHRM1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.